Objective
The high costs and long timelines associated with drug development are a major burden to society. The healthcare industry is increasingly looking for systems and processes to reduce the costs of developing and testing new drugs. Commercial wearable medical devices have recently found their ways into clinical trials, with pharma companies looking for new tools to monitor patients enrolled in clinical trials. Although such wearables can track a plethora of patient parameters and offer advantages that stand to improve the way in which clinical trials are designed and conducted, they only measure physical parameters of patients and fail to measure biochemical parameters that are directly relevant to drug development (biomarkers).
Xsensio has leveraged the most advanced innovations from the fields of nanotechnology, biochemistry, and microfluidics to develop its proprietary Lab-on-Skin™ platform. At its core, the Lab-on-Skin™ platform contains an innovative functionalized sensor chip that is capable of measuring biomarkers in sweat. With the remote, continuous, and real-time monitoring of biomarkers, ultra-low power consumption, and optimized design for mass-production, the Lab-on-Skin™ platform is highly attractive for integration into wearable devices for 24/7 monitoring of patients. In this project, Xsensio will perform a feasibility study to (1) select a panel of biomarkers that maximize the (clinical) applications of the Lab-on-Skin™ platform, (2) obtain quantitative and qualitative market data, (3) construct roadmaps for navigating the regulatory landscape, (4) strengthen and expand its current IP position, and (5) consolidate all current and future findings into a business plan.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- engineering and technologynanotechnology
- medical and health scienceshealth sciencessubstance abuse
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
- engineering and technologymedical engineeringwearable medical technology
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
1015 Lausanne
Switzerland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.